Xinjian Wang
Papers
1
Total Citations
4
H-Index
1
About
Xinjian Wang is a leading surgical oncologist whose research focuses on optimizing perioperative care for gastric cancer patients, particularly those undergoing advanced minimally invasive procedures after neoadjuvant chemotherapy. His major contributions center on the role of the gut microbiome in surgical recovery, most notably through his pioneering work on perioperative probiotic supplementation. Wang’s most cited study, the multicenter GISSG2023-01 trial protocol (2025, 4 citations), investigates whether probiotics can improve short-term clinical outcomes in patients undergoing laparoscopic or robotic radical gastrectomy. This work addresses a critical gap in oncologic surgery: managing the compounded physiological stress of chemotherapy and major resection. By designing a rigorous randomized controlled trial, Wang is helping to establish evidence-based protocols that could reduce postoperative complications and enhance recovery. His research bridges gastrointestinal oncology, nutritional immunology, and surgical innovation, with potential to transform standard care for advanced gastric cancer patients. Wang’s contributions are particularly relevant as robotic and laparoscopic techniques become more widespread, making his work essential reading for surgeons and researchers seeking to improve outcomes through microbiome-targeted interventions.
Research Focus
Key Achievements
Top Papers
- 1